December 29, 2016 / 12:08 PM / 8 months ago

BRIEF-Bavarian Nordic starts trial of CV301 in combination with Nivolumab

Dec 29 (Reuters) - Bavarian Nordic A/S :

* Initiates trial of CV301 in combination with Nivolumab in patients with lung cancer

* Says CV301 is an immunotherapy candidate which is being developed under a CRADA with National Cancer Institute (NCI) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below